MedImmune (AZ) reports results of TULIP 1 P-III for anifrolumab in systemic lupus erythematosus
Shots:
- TULIP 1 P-III trial with didn’t meet SRI4@12mos in moderate-to-severe SLE patients
- TULIP study includes two P-III trials TULIP 1 (N=460) in ratio (1:2:2) for 52 wks. administering of 150-300mg anifrolumab IV or PBO q4w; TULIP 2(N=373) in ratio (1:1) 300mg anifrolumab IV or PBO q4w- evaluating safety and efficacy
- Anifrolumab is also being assessed in P-III SLE long-term extension trial- a P-II trial using subcutaneous delivery in SLE and a P-II trial for lupus nephritis
Ref: AstraZeneca | Image: Pharma Board room
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com